Overview
RyboDyn, a biotechnology company based in San Diego, has raised $10 million in seed funding to advance its AI-powered cancer target discovery platform. The funding will help transition the company from foundational discovery to scaled execution, focusing on uncovering cryptic proteins from non-canonical RNA to identify new cancer targets. RyboDyn's platform has expanded the discovery of novel RNA species and identified over 80,000 cryptic peptides, aiming to address bottlenecks in oncology drug development.
Products
Loading...
Recent Deals
RyboDyn, a biotechnology company based in San Diego, has raised $10 million in seed funding to advance its AI-powered cancer target discovery platform. The funding will help transition the company from foundational discovery to scaled execution, focusing on uncovering cryptic proteins from non-canonical RNA to identify new cancer targets. RyboDyn's platform has expanded the discovery of novel RNA species and identified over 80,000 cryptic peptides, aiming to address bottlenecks in oncology drug development.